On Friday, Shares of Array Biopharma Inc (NASDAQ:ARRY), gained 3.05% to $7.77.
On June 1, Array Biopharma, wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were showcased at the 2015 annual meeting of the American Society of Clinical Oncology (ASCO). At the meeting, preliminary data for the combination of binimetinib and encorafenib from a Phase 1b/2 dose escalation and expansion study in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive were shared during an oral presentation. Results from the study indicate that binimetinib and encorafenib may be safely combined and show encouraging clinical activity consistent with MEK/BRAF inhibitor expectations in patients with BRAF-mutant melanoma who are BRAF inhibitor treatment naive. In addition, a differentiated safety profile relative to other MEK/BRAF inhibitor combinations is emerging in the dose range presently being used in the Phase 3 COLUMBUS trial. Array anticipates updated BRAF melanoma data from the ongoing Phase 2 combination trial (LOGIC-2) of binimetinib and encorafenib followed by the addition of a third targeted agent identified based on genetic testing at the time of progression will be presented to a scientific conference later this year. LOGIC-2 utilizes the same dose of binimetinib and encorafenib presently being studied in the COLUMBUS trial.
In the study, patients were treated with binimetinib 45 mg twice daily (BID) and increasing doses of encorafenib once daily (QD) (over the range of 50 to 800 mg and counting doses of 400 and 450 mg, which are comparable to the 450 mg dose being used in the Phase 3 COLUMBUS trial), followed by an expansion phase at the maximum tolerated dose of 600 mg QD. The objective response rate (confirmed complete response or partial response) stated in the trial was 75 percent (41 of 55) for BRAF-naive patients, counting 78 percent (7 of 9) of patients treated with the encorafenib 400/450 mg dose. The estimated median overall progression-free survival for BRAF-naive patients was 11.3 months. These results are consistent with MEK/RAF inhibitor expectations in BRAF-mutant melanoma patients.
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific. The company’s products in Phase III clinical trials comprise Binimetinib and Encorafenib for the treatment of cancer.
Shares of TASER International, Inc. (NASDAQ:TASR), declined -1.14% to $34.56, during its last trading session.
TASER International, declared multiple orders of its TASER brand next generation Smart Weapons. These orders were received and shipped in the second quarter.
Noteworthy TASER Weapon orders:
- Arizona Department of Public Safety (AZ): 60 TASER® X2™ Smart Weapons, Officer Safety Plan
- Atlanta Police Department (GA): 200 X2s with TASER® Cam™ HD recorders
- Buncombe County Sheriff’s Office (NC): 50 X2s, TASER Assurance Plan (TAP)
- Camden County Prosecutors Office (NJ): 40 X2s with 34 TASER Cam HD recorders
- Cleveland Metro Parks (OH): 85 TASER® X26P™ Smart Weapons
- Cook County Sheriff’s Office (IL): 95 X2s and 100 X26Ps
- Dallas Police Department (TX): 75
- Denver Police Department (CO): 100 X26Ps
- Eugene Police Department (OR): 60 X26Ps
- Georgia Department of Corrections (GA): 140 X2s
- International Order: 110 X26Ps
- Mall of America Security Department (MN): 82 X26Ps
- Metropolitan Nashville Police Department (TN): 100 X26Ps
- Miami Police Department (FL): 180 X2s
- Montgomery County Sheriff’s Department (TX): 44 X26Ps
- Multnomah County Sheriff’s Office (OR): 100 X26Ps
- New Orleans Police Department (LA): 350 X26Ps with TASER Cam HD recorders, upgrade
- Oakland Police Department (CA): 60 X26Ps
- Ohio Department of Public Safety Patrol Academy (OH): 70 X26Ps
- Ontario Provincial Police (ON): 279 X2s
- Orange County Department of Corrections (FL): 43 X26Ps with 15 TASER Cam HD recorders
- Ottawa Police Service (ON): 100 X2s
- Peel Regional Police Tactical Unit (ON): 100 X2s
- San Antonio Park Police (TX): 40 X26Ps
- Southern Illinois University Department of Public Safety (IL): 42 X26Ps.
TASER International, Inc. develops, manufactures, and sells conducted electrical weapons (CEWs) worldwide. It operates through two segments, TASER Weapons and AXON. The company’s CEW products transmit electrical pulses along the wires and into the body affecting the sensory and motor functions of the peripheral nervous system.
At the end of Friday’s trade, Shares of Entergy Corporation (NYSE:ETR), lost -0.65% to $71.57.
Entergy Corporation, declared that Robert Hall III has been named vice president, federal governmental affairs. Based in Entergy’s Washington, D.C., office, Hall’s responsibilities comprise developing and implementing the company’s stakeholder engagement strategies with elected officials and key policymakers.
“Rob brings his longstanding energy and policy acumen to Entergy and will be a key member of the team working to enhance Entergy’s voice on the industry’s continuously changing policy debate in Washington,” said Rod West, Entergy’s executive vice president and chief administrative officer. “Hall’s extensive experience working on key energy and tax issues, his in-depth knowledge of the legislative process in the Senate and the House and his proven ability to engage key stakeholders will be extremely valuable as he assumes this important role.”
Entergy Corporation, together with its auxiliaries, engages in the electric power production and retail electric distribution operations in the United States. It operates in two segments, Utility and Entergy Wholesale Commodities.
Finally, Interface, Inc. (NASDAQ:TILE), ended its last trade with 1.02% gain, and close at $24.65.
Interface, offered an update on the progress of Net-Works in the Philippines. Funded in part by United Kingdom government’s Darwin Initiative, the Net-Works program is primed for global expansion. Net-Works is the first inclusive business model of its kind to combine the conservation and livelihood expertise of ZSL and the business know-how of Interface to integrate fishing communities in the Philippines into the global carpet company’s supply chain as a source of recycled nylon.
Interface, Inc. designs, produces, and sells modular carpet products primarily in the Americas, Europe, and the Asia-Pacific. It offers modular carpets under the Interface and FLOR brands; and carpet tiles under the GlasBacRE brand name for use in commercial interiors, counting offices, healthcare facilities, airports, educational and other institutions, hospitality spaces, and retail facilities, in addition to residential interiors.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
